Back to top

Image: Bigstock

Here's Why You Should Hold on to Insulet (PODD) Stock Now

Read MoreHide Full Article

Insulet Corporation (PODD - Free Report) has been progressing well with its strategies of expanding Omnipod’s market access and developing the Omnipod Horizon system. The company already seems to be on track to achieve revenues of $1 billion by 2021. However, a tough competitive landscape and macroeconomic uncertainties are likely to offset the positives to some extent.

The $9.04-billion commercial developer of insulin treatment expects a skyrocketing earnings growth rate of 164.3% for the next year. Also, the company has a trailing four-quarter positive earnings surprise of 101.4%, on average.

In the past six months, the stock has lost 4.6% compared with 33.1% decline of its industry

Let’s delve deeper into the factors that substantiate the company’s Zacks Rank #3 (Hold).

Advancement of U.S. Manufacturing Facility: Management seems to be particularly upbeat about the manufacturing unit in Acton, MA. Insulet expects that following the startup-related activities, the facility will allow it to lower manufacturing costs, increase supply redundancy, add capacity to meet the need of its North America customer base and support growth. Management expects to continue increasinginvestment in the facility in 2020 to support growth of its business.

 

 

Omnipod’s Market Access Expansion: Insulet has been consistently benefitting from the full commercial launch of the Omnipod DASH system in the United States in early 2019. Subsequently, the company launched the Omnipod DASH system in select Europe markets in December 2019. Per the company, a record number of new users have adopted Omnipod in the United States since DASH’s launch. Insulet is on track to roll out the DASH system across Europe and Canada in 2020.

Strength in Omnipod Horizon: Insulet broadened its collaboration with DexCom to integrate DexCom’s G6 and future G7 continuous glucose monitoring systems into the Omnipod Horizon system. Insulet is also on track with the expansion of partnership with Abbott to integrate Abbott’s next-generation Libre glucose sensing technology into the next-generation Omnipod Horizon system. Hence Omnipod Horizon is expected to continue driving growth for the company in the long term.

However, a few factors are deterring the company’s growth prospects.

Economic Uncertainty: Weaker global economic conditions, particularly due to the coronavirus outbreak, may deflate demand for Insulet’s products, increase competition, exert pressure on prices plus dent supply, and lengthen sales cycle. The company is also susceptible to the risk of reduction in healthcare spending in the United States, Canada and Europe due to an economic slump.

Competitive Pressure:  Insulet operates in a highly competitive environment, dominated by firms, ranging from large multinational corporations with significant resources to start-ups. The company’s Omnipod System primarily competes with Medtronic’s MiniMed.

Estimate Trend

The Zacks Consensus Estimate for Insulet’s first-quarter 2020 revenues is pegged at $189.5 million, suggesting an 18.8% rise from the year-ago reported number.

However, the company is witnessing a negative estimate revision trend for 2020. Over the past 30 days, the Zacks Consensus Estimate for its earnings has declined 17.6% to 56 cents per share.

Key Picks

Some better-ranked stocks from the broader medical space are ResMed Inc. (RMD - Free Report) , Medtronic plc (MDT - Free Report)  and Hill-Rom Holdings, Inc. (HRC - Free Report) .

ResMed has a projected long-term earnings growth rate of 12%. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Medtronic’s long-term earnings growth rate is estimated at 7.4%. The company presently carries a Zacks Rank #2.

Hill-Rom’s long-term earnings growth rate is estimated at 11.1%. It currently carries a Zacks Rank #2.

More Stock News: This Is Bigger than the iPhone!

 It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

 Click here for the 6 trades >>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Medtronic PLC (MDT) - free report >>

ResMed Inc. (RMD) - free report >>

Hill-Rom Holdings, Inc. (HRC) - free report >>

Insulet Corporation (PODD) - free report >>